Publications by authors named "S Krug-Gourley"
In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events.
Am Heart J
July 2020
Article Synopsis
- * Key targets included maintaining low-density lipoprotein cholesterol (LDL-C) levels below 100 mg/dL and hemoglobin A1c (HbA1c) levels below 7% for diabetic patients, which were linked to better patient outcomes.
- * Results showed that lower LDL-C levels significantly reduced MACE rates, while no distinct impact was noted for blood pressure targets, indicating that achieving lipid and glucose control is crucial for patient health.
Article Synopsis
- A study assessed cognitive performance using the Montreal Cognitive Assessment in 10,634 patients with coronary heart disease, comparing those treated with darapladib and those given a placebo, finding no significant difference in scores between the two groups.
- Factors like age, education level, and cardiovascular risk factors (e.g., history of stroke, low exercise, poor cholesterol levels) were found to significantly affect the likelihood of mild cognitive impairment among participants.
- The results indicated that while cognitive performance was linked to modifiable cardiovascular risk factors and education, it was not influenced by the darapladib treatment.
Background And Aims: Lipoprotein-associated phospholipase A (Lp-PLA), an enzymatic inflammatory biomarker primarily bound to low-density lipoprotein cholesterol, is associated with an approximate twofold increased risk of cardiovascular disease and stroke. Despite indications that circulating Lp-PLA is sensitive to statins, it remains largely unknown whether statin usage exerts local effects on Lp-PLA expression at the site of atheromatous plaque.
Methods: Carotid plaques (n = 38) were prospectively collected from symptomatic (n = 18) and asymptomatic (n = 20) patients with (n = 20) or without (n = 18) documented statin history.
Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.
J Am Heart Assoc
September 2017
Background: Greater understanding of differences between men and women with coronary heart disease is needed.
Methods And Results: In this post hoc analysis of the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial, we described psychosocial factors, treatments, and outcomes of men versus women with stable coronary heart disease and explored the association of sex with psychosocial characteristics and cardiovascular risk. Cox proportional hazards models were used to assess the relationship between sex and outcomes.
Background: The major determinants and prognostic importance of self-reported health in patients with stable coronary heart disease are uncertain.
Methods And Results: The STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial randomized 15 828 patients with stable coronary heart disease to treatment with darapladib or placebo. At baseline, 98% of participants completed a questionnaire that included the question, "Overall, how do you feel your general health is now?" Possible responses were , and .